Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-12-08 Purchase |
2021-12-10 8:33 pm |
Xilio Therapeutics Inc. | XLO | Bain Capital Life Sciences Investors LLC Bain Capital Life Sciences Fund II L.P. Bain Capital Life Sciences Investors II LLC BCLS II Investco LP BCLS II Investo (GP) LLC BCIP Life Sciences Associates LP 10% Owner |
42,469 | $9.6579 | $410,161 | 2,805,413 (Indirect) |
View |
| 2021-10-26 Purchase(A) |
2021-11-03 4:20 pm |
Xilio Therapeutics Inc. | XLO | SV7 Impact Medicine Fund LP SV7 (IMF) GP LLP 10% Owner |
625,000 | $16 | $10,000,000 | 3,227,264 (Indirect Direct) |
View |
| 2021-10-26 Purchase |
2021-10-28 7:15 pm |
Xilio Therapeutics Inc. | XLO | Flynn James E Deerfield Mgmt L.P. DEERFIELD PARTNERS L.P. DEERFIELD MANAGEMENT COMPANY L.P. (SERIES C) Deerfield Mgmt V L.P. Possible Member of 10% Group 10% Owner |
775,000 | $16 | $12,400,000 | 1,143,972 (Indirect) |
View |
| 2021-10-26 Purchase |
2021-10-26 5:30 pm |
Xilio Therapeutics Inc. | XLO | RiverVest Venture Fund IV L.P. 10% Owner |
250,000 | $16 | $4,000,000 | 1,441,444 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-06-12 Option Award |
2023-06-13 4:30 pm |
N/A 2033-06-11 |
Xilio Therapeutics Inc. | XLO | ROSS ROBERT W. Director |
13,200 | $0 | 13,200 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-13 4:30 pm |
N/A 2033-06-11 |
Xilio Therapeutics Inc. | XLO | Heyman Tomas J. Director |
13,200 | $0 | 13,200 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-13 4:30 pm |
N/A 2033-06-11 |
Xilio Therapeutics Inc. | XLO | Xu Yuan Director |
13,200 | $0 | 13,200 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-13 4:30 pm |
N/A 2033-06-11 |
Xilio Therapeutics Inc. | XLO | Bonstein Sara Director |
13,200 | $0 | 13,200 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-13 4:30 pm |
N/A 2033-06-11 |
Xilio Therapeutics Inc. | XLO | Rossi Christina Director |
13,200 | $0 | 13,200 (Direct) |
View |
| 2023-06-12 Option Award |
2023-06-13 4:30 pm |
N/A 2033-06-11 |
Xilio Therapeutics Inc. | XLO | Clancy Paul J Director |
13,200 | $0 | 13,200 (Direct) |
View |
| 2023-04-01 Option Award |
2023-04-03 4:11 pm |
N/A 2033-03-31 |
Xilio Therapeutics Inc. | XLO | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING |
55,000 | $0 | 55,000 (Direct) |
View |
| 2023-01-01 Option Award |
2023-01-04 4:14 pm |
N/A 2032-12-31 |
Xilio Therapeutics Inc. | XLO | Russo Rene CEO |
350,000 | $0 | 350,000 (Direct) |
View |
| 2023-01-01 Option Award |
2023-01-04 4:11 pm |
N/A 2032-12-31 |
Xilio Therapeutics Inc. | XLO | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D |
136,500 | $0 | 136,500 (Direct) |
View |
| 2023-01-01 Option Award |
2023-01-04 4:09 pm |
N/A 2032-12-31 |
Xilio Therapeutics Inc. | XLO | English Edward C PRINCIPAL ACCOUNTING OFFICER |
24,000 | $0 | 24,000 (Direct) |
View |
Ownership |
2022-11-16 4:16 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | English Edward C Principal Accounting Officer |
0 | $0 | 79,399 (Direct) |
View |
| 2022-09-15 Option Award |
2022-09-16 4:15 pm |
N/A 2032-09-14 |
Xilio Therapeutics Inc. | XLO | Heyman Tomas J. Director |
26,400 | $0 | 26,400 (Direct) |
View |
| 2022-06-15 Option Award(A) |
2022-06-23 7:30 pm |
N/A 2032-06-14 |
Xilio Therapeutics Inc. | XLO | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D |
20,000 | $0 | 20,000 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:31 pm |
N/A 2032-06-14 |
Xilio Therapeutics Inc. | XLO | Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D |
20,000 | $0 | 20,000 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:30 pm |
N/A 2032-06-14 |
Xilio Therapeutics Inc. | XLO | Rossi Christina Director |
13,200 | $0 | 13,200 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:30 pm |
N/A 2032-06-14 |
Xilio Therapeutics Inc. | XLO | Ross Michael Jay Director |
13,200 | $0 | 13,200 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:30 pm |
N/A 2032-06-14 |
Xilio Therapeutics Inc. | XLO | Clancy Paul J Director |
13,200 | $0 | 13,200 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:30 pm |
N/A 2032-06-14 |
Xilio Therapeutics Inc. | XLO | Xu Yuan Director |
13,200 | $0 | 13,200 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:30 pm |
N/A 2032-06-14 |
Xilio Therapeutics Inc. | XLO | Bonstein Sara Director |
13,200 | $0 | 13,200 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:08 pm |
N/A 2032-06-14 |
Xilio Therapeutics Inc. | XLO | ROSS ROBERT W. Director |
26,400 | $0 | 26,400 (Direct) |
View |
| 2022-02-22 Option Award |
2022-02-24 5:30 pm |
N/A 2032-02-21 |
Xilio Therapeutics Inc. | XLO | Giovine Salvatore CHIEF FINANCIAL OFFICER |
49,500 | $0 | 49,500 (Direct) |
View |
| 2022-02-22 Option Award |
2022-02-24 5:30 pm |
N/A 2032-02-21 |
Xilio Therapeutics Inc. | XLO | Huber Martin H. Jr. PRESIDENT OF R&D AND CMO |
65,000 | $0 | 65,000 (Direct) |
View |
| 2022-02-22 Option Award |
2022-02-24 5:30 pm |
N/A 2032-02-21 |
Xilio Therapeutics Inc. | XLO | Russo Rene CEO AND PRESIDENT |
150,000 | $0 | 150,000 (Direct) |
View |
| 2022-01-04 Option Award |
2022-01-06 6:48 pm |
N/A 2032-01-03 |
Xilio Therapeutics Inc. | XLO | Xu Yuan Director |
26,400 | $0 | 26,400 (Direct) |
View |
| 2021-12-22 Option Award(A) |
2022-01-04 5:32 pm |
N/A 2031-12-21 |
Xilio Therapeutics Inc. | XLO | Russo Rene CEO AND PRESIDENT |
100,000 | $0 | 100,000 (Direct) |
View |
| 2021-12-22 Option Award |
2021-12-23 7:06 pm |
N/A 2031-12-21 |
Xilio Therapeutics Inc. | XLO | Russo Rene CEO AND PRESIDENT |
100,000 | $0 | 100,000 (Direct) |
View |
Ownership |
2021-11-05 6:26 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Bain Capital Life Sciences Investors LLC Bain Capital Life Sciences Fund II L.P. Bain Capital Life Sciences Investors II LLC BCLS II Investco LP BCLS II Investo (GP) LLC BCIP Life Sciences Associates LP 10% Owner |
0 | $0 | 2,762,944 (Indirect) |
View |
| 2021-10-26 Conversion(A) |
2021-11-03 4:20 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | SV7 Impact Medicine Fund LP SV7 (IMF) GP LLP 10% Owner |
26,022,654 | $0 | 3,227,264 (Direct) |
View |
| 2021-10-26 Conversion |
2021-10-28 7:15 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Flynn James E Deerfield Mgmt L.P. DEERFIELD PARTNERS L.P. DEERFIELD MANAGEMENT COMPANY L.P. (SERIES C) Deerfield Mgmt V L.P. Possible Member of 10% Group 10% Owner |
15,129,450 | $0 | 1,143,972 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-28 3:57 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | FIL Ltd See Remark 1 |
2,296,403 | $0 | 218,705 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-28 3:45 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | FMR LLC See Remark 1 |
19,754,248 | $0 | 30,780 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-28 12:55 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | SV7 Impact Medicine Fund LP SV7 (IMF) GP LLP 10% Owner |
26,022,654 | $0 | 2,602,264 (Direct) |
View |
| 2021-10-26 Conversion |
2021-10-26 8:31 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | TAKEDA PHARMACEUTICAL CO LTD Takeda Ventures Inc. 10% Owner |
2,950,242 | $0 | 1,475,121 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-26 5:30 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | RiverVest Venture Fund IV L.P. 10% Owner |
1,191,444 | $0 | 1,441,444 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-26 5:06 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Merck KGaA 10% Owner |
7,148,664 | $0 | 680,825 (Indirect) |
View |